Advanced-phase chronic myeloid leukemia
- 31 January 2003
- journal article
- Published by Elsevier BV in Seminars in Hematology
- Vol. 40 (1), 79-86
- https://doi.org/10.1016/s0037-1963(03)70045-6
Abstract
No abstract availableThis publication has 47 references indexed in Scilit:
- High frequency of point mutations clustered within the adenosine triphosphate–binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistanceBlood, 2002
- Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia ChromosomeThe New England Journal of Medicine, 2001
- Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid LeukemiaThe New England Journal of Medicine, 2001
- Chronic Myelogenous Leukemia: Biology and TherapyAnnals of Internal Medicine, 1999
- RASand Leukemia: From Basic Mechanisms to Gene-Directed TherapyJournal of Clinical Oncology, 1999
- Suppression of cytogenetic clonal evolution with interferon alfa therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.Journal of Clinical Oncology, 1998
- Molecular Follow-Up of Disease Progression and Interferon Therapy in Chronic Myelocytic LeukemiaBlood, 1997
- A pilot study of all-trans retinoic acid in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.Leukemia, 1997
- Treatment of chronic myelogenous leukemia with nucleoside analogs deoxycoformycin and fludarabine.Leukemia, 1997
- Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cellsNature Medicine, 1996